Research progress on risk factors of recurrent atrial fibrillation after radiofrequency catheter ablation_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZHANG Qi , YAO Xingxing , LIU Honghao , SONG Tao , JIAO Zhouyang ,  LIU Chao

Department of Cardiac Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, P.R.China;

Corresponding?author：

LIU Chao, Email: Liubeilun@sohu.com

Keywords：

Atrial fibrillation; radiofrequency catheter ablation; recurrence

DOI：

10.7507/1007-4848.201511017

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Atrial fibrillation (AF) is one of the most common clinical arrhythmia. In recent years, basic researches on AF have made a great progress. Radiofrequency catheter ablation (RFCA) has been widely used as a nonpharmacological treatment for AF. However, recurrence rate of AF is high even after RFCA. So we need to find the influencing factors of the recurrence of AF early. Choosing patients who have better indications can improve the success rate of RFCA and reduce recurrence rate.

Citation： ZHANG Qi, YAO Xingxing, LIU Honghao, SONG Tao, JIAO Zhouyang, LIU Chao. Research progress on risk factors of recurrent atrial fibrillation after radiofrequency catheter ablation. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2017, 24(8): 649-651. doi: 10.7507/1007-4848.201511017 Copy

1.	周自強, 胡大一, 陳捷, 等. 中國心房顫動現狀的流行病學研究.中華內科雜志, 2004, 43(7): 491-494.
2.	Li Y, Wu YF, Chen KP, et al. Prevalence of atrial fibrillation in China and its risk factors. Biomed Environ Sci, 2013, 26(9): 709-716.
3.	方東平, 郭成軍, 李果, 等. 慢性心房顫動射頻消融術后應用氯沙坦聯合胺碘酮治療對心房顫動復發及心房結構的影響. 新鄉醫學院學報, 2013, 30(9): 730-732.
4.	張鶴萍, 胡大一. 非心瓣膜疾病性心房顫動與血栓栓塞. 中華心血管病雜志, 2005, 33(10): 966-968.
5.	European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology(ESC). Eur Heart J, 2010, 31(19): 2369-2429.
6.	武忠, 陳保俊, 曹彬, 等. 心內直視下射頻消融改良迷宮術治療心房顫動. 中國胸心血管外科臨床雜志, 2007, 14(4): 308-309.
7.	鄔曉臣, 張進寶. 二尖瓣置換同期行雙極射頻消融術治療風濕性二尖瓣病變合并心房顫動的療效分析. 中國胸心血管外科臨床雜志, 2014, 21(6): 827-829.
8.	秦牧, 于勝波, 趙慶彥, 等. 抑郁對心房顫動患者環肺靜脈射頻消融術后復發的影響. 中華心律失常學雜志, 2011, 15(4): 268-271.
9.	Kottkamp H. Catheter ablation of atrial fibrillation: on the pathophysiology of the arrhythmia and the impact of cardiac risk factor management. J Am Coll Cardiol, 2014, 64(21): 2232-2234.
10.	沈啟明, 劉伏元. 陣發性心房顫動患者射頻消融術后心房顫動晚期復發的相關因素. 中國臨床保健雜志, 2013, 16(3): 268-270.
11.	符竣, 王波, 陶涼, 等. 兩種不同射頻消融方式治療風濕性心瓣膜病合并永久性心房顫動的療效比較. 中國胸心血管外科臨床雜志, 2013, 20(3): 304-307.
12.	付明浦, 薛松, 黃日太, 等. 心內直視手術同期行單極或雙極射頻消融治療心房顫動的效果比較. 中國胸心血管外科臨床雜志, 2015, 22(9): 851-854.
13.	Sestito A, Molina E. Atrial fibrillation and the pharmacological treatment: the role of propafenone. Eur Rev Med Pharmacol Sci, 2012,16(2): 242-253.
14.	楊嵩, 張希, 唐白云, 等. 永久性心房顫動外科雙極射頻消融術的效果. 中國胸心血管外科臨床雜志, 2012, 19(3): 254-257.
15.	張新勇, 馬長生. 接受射頻消融治療的女性房顫患者危險因素分析. 中國醫學前沿雜志(電子版), 2010, 2(3): 59-62.
16.	王瑩惠, 王波, 付琳. 房顫射頻消融術后 AF 早期復發的預測因素. 心臟雜志, 2014, 26(6): 734-736.
17.	林德仿. 陣發性心房顫動患者射頻消融術后心房顫動晚期復發的相關因素分析. 現代醫院, 2014, 14(12): 47-50.
18.	Annoura M, Ogawa M, Kumagai K, et al. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology, 1999, 92(1): 21-27.
19.	Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102(18): 2165-2168.
20.	梁海雁, 駢晶, 姚傳臣. 瑞舒伐他汀對陣發性房顫患者 C 反應蛋白、左心房內徑及房顫復發率的影響. 河北醫藥, 2012, 34(19): 2907-2908.
21.	Letsas KP, Weber R, Burkle G, et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace, 2009, 11(2): 158-163.
22.	Pandozi C, Santini M. Update on atrial remodelling owing to rate; does atrial fibrillation always 'beget' atrial fibrillation? Eur Heart J, 2001, 22(7): 541-553.
23.	李菲, 孟旭. 術前左心房內徑對外科射頻術治療心房顫動療效的影響. 中國胸心血管外科臨床雜志, 2013, 20(1): 38-42.
24.	唐宏萍, 辛輝, 魏延津. 瑞舒伐他汀的劑量大小對房顫射頻消融術后復發的影響. 山東醫學高等專科學校學報, 2015, 37(1): 63-67.
25.	Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fibrillation, inflammation and statins. Hellenic J Cardiol, 2006, 47(2): 51-53.
26.	謝詠梅, 寶花, 金花. 他汀類藥物在治療房顫中的作用分析. 內蒙古醫學雜志, 2013, 45(1): 99-100.
27.	Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart, 2008, 29(13): 1662-1669.
28.	Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol, 2011, 108(1): 47-51.
29.	Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: Clinical impact of continuous positive airway pressure therapy. Heart Rhythm, 2013, 10(3): 331-337.
30.	Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart, 2010, 159(6): 1102-1107.
31.	Naruse Y, Tada H, Sekiguchi Y, et al. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: A mid-term follow-up. Heart Rhythm, 2011, 8(3): 335-341.
32.	Leong-Sit P, Roux JF, Zado E, et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol, 2011, 4: 11-14.
33.	den Uijl DW, Delgado V, Bertini M, et al. Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation. Heart, 2011, 97(22): 1847-1851.
34.	Catena C, Colussi G, Marzano L, et al. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res, 2012, 44(3): 181-187.
35.	雷濤, 劉小慧, 羅太陽, 等. 培哚普利聯合醛固酮受體拮抗劑對心房纖顫犬心房電重構的影響. 心肺血管病雜志, 2010, 29(3): 233-237.
36.	Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in atrial fibrosis: Mechanisms and fibrillation. J Mol Cell Cardiol, 2010, 48(3): 461-467.
37.	盧艷雨, 余江坤, 魯艷嬌, 等. 螺內酯對持續性房顫患者射頻消融術后的臨床療效分析. 河南醫學研究, 2015, 24(4): 12-14.
38.	周勇, 李莉, 徐志厶, 等. 心內膜微波消融治療永久性心房顫動. 中華心血管病雜志, 2008, 36(5): 402-403.
39.	伍繼初, 羅參香, 歐陽澤偉. 胺碘酮及氯沙坦對慢性房顫射頻消融術后心房結構及房顫復發的影響. 中國臨床藥理學與治療學, 2015, 2(3): 318-322.
40.	梁珍玲, 孫葉海, 彭衛平. 厄貝沙坦聯合胺碘酮治療陣發性心房顫動的療效. 中國老年學雜志, 2012, 32(13): 2836-2837.
41.	Beukema WP, Sie HT, Misier AR, et al. Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified Maze procedure. Eur J Cardiothorac Surg, 2008, 34(4): 771-775.
42.	Fasol R, Mdinhart J, Binder T. A modified and simplified radiofrequency ablation in patients with mitral valve disease. J Thorac Cardiovasc Surg, 2005, 129(1): 215-217.
43.	Parvez B, Shoemaker MB, Muhammad R, et al. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm, 2013, 10(6): 849-855..
44.	Benjamin Shoemaker M, Muhammad R, Parvez B, et al. Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm, 2013, 10(3): 394-400.

1. 周自強, 胡大一, 陳捷, 等. 中國心房顫動現狀的流行病學研究.中華內科雜志, 2004, 43(7): 491-494.
2. Li Y, Wu YF, Chen KP, et al. Prevalence of atrial fibrillation in China and its risk factors. Biomed Environ Sci, 2013, 26(9): 709-716.
3. 方東平, 郭成軍, 李果, 等. 慢性心房顫動射頻消融術后應用氯沙坦聯合胺碘酮治療對心房顫動復發及心房結構的影響. 新鄉醫學院學報, 2013, 30(9): 730-732.
4. 張鶴萍, 胡大一. 非心瓣膜疾病性心房顫動與血栓栓塞. 中華心血管病雜志, 2005, 33(10): 966-968.
5. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology(ESC). Eur Heart J, 2010, 31(19): 2369-2429.
6. 武忠, 陳保俊, 曹彬, 等. 心內直視下射頻消融改良迷宮術治療心房顫動. 中國胸心血管外科臨床雜志, 2007, 14(4): 308-309.
7. 鄔曉臣, 張進寶. 二尖瓣置換同期行雙極射頻消融術治療風濕性二尖瓣病變合并心房顫動的療效分析. 中國胸心血管外科臨床雜志, 2014, 21(6): 827-829.
8. 秦牧, 于勝波, 趙慶彥, 等. 抑郁對心房顫動患者環肺靜脈射頻消融術后復發的影響. 中華心律失常學雜志, 2011, 15(4): 268-271.
9. Kottkamp H. Catheter ablation of atrial fibrillation: on the pathophysiology of the arrhythmia and the impact of cardiac risk factor management. J Am Coll Cardiol, 2014, 64(21): 2232-2234.
10. 沈啟明, 劉伏元. 陣發性心房顫動患者射頻消融術后心房顫動晚期復發的相關因素. 中國臨床保健雜志, 2013, 16(3): 268-270.
11. 符竣, 王波, 陶涼, 等. 兩種不同射頻消融方式治療風濕性心瓣膜病合并永久性心房顫動的療效比較. 中國胸心血管外科臨床雜志, 2013, 20(3): 304-307.
12. 付明浦, 薛松, 黃日太, 等. 心內直視手術同期行單極或雙極射頻消融治療心房顫動的效果比較. 中國胸心血管外科臨床雜志, 2015, 22(9): 851-854.
13. Sestito A, Molina E. Atrial fibrillation and the pharmacological treatment: the role of propafenone. Eur Rev Med Pharmacol Sci, 2012,16(2): 242-253.
14. 楊嵩, 張希, 唐白云, 等. 永久性心房顫動外科雙極射頻消融術的效果. 中國胸心血管外科臨床雜志, 2012, 19(3): 254-257.
15. 張新勇, 馬長生. 接受射頻消融治療的女性房顫患者危險因素分析. 中國醫學前沿雜志(電子版), 2010, 2(3): 59-62.
16. 王瑩惠, 王波, 付琳. 房顫射頻消融術后 AF 早期復發的預測因素. 心臟雜志, 2014, 26(6): 734-736.
17. 林德仿. 陣發性心房顫動患者射頻消融術后心房顫動晚期復發的相關因素分析. 現代醫院, 2014, 14(12): 47-50.
18. Annoura M, Ogawa M, Kumagai K, et al. Cholesterol paradox in patients with paroxysmal atrial fibrillation. Cardiology, 1999, 92(1): 21-27.
19. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 2000, 102(18): 2165-2168.
20. 梁海雁, 駢晶, 姚傳臣. 瑞舒伐他汀對陣發性房顫患者 C 反應蛋白、左心房內徑及房顫復發率的影響. 河北醫藥, 2012, 34(19): 2907-2908.
21. Letsas KP, Weber R, Burkle G, et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: the potential role of inflammation. Europace, 2009, 11(2): 158-163.
22. Pandozi C, Santini M. Update on atrial remodelling owing to rate; does atrial fibrillation always 'beget' atrial fibrillation? Eur Heart J, 2001, 22(7): 541-553.
23. 李菲, 孟旭. 術前左心房內徑對外科射頻術治療心房顫動療效的影響. 中國胸心血管外科臨床雜志, 2013, 20(1): 38-42.
24. 唐宏萍, 辛輝, 魏延津. 瑞舒伐他汀的劑量大小對房顫射頻消融術后復發的影響. 山東醫學高等專科學校學報, 2015, 37(1): 63-67.
25. Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fibrillation, inflammation and statins. Hellenic J Cardiol, 2006, 47(2): 51-53.
26. 謝詠梅, 寶花, 金花. 他汀類藥物在治療房顫中的作用分析. 內蒙古醫學雜志, 2013, 45(1): 99-100.
27. Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart, 2008, 29(13): 1662-1669.
28. Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol, 2011, 108(1): 47-51.
29. Naruse Y, Tada H, Satoh M, et al. Concomitant obstructive sleep apnea increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial fibrillation: Clinical impact of continuous positive airway pressure therapy. Heart Rhythm, 2013, 10(3): 331-337.
30. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart, 2010, 159(6): 1102-1107.
31. Naruse Y, Tada H, Sekiguchi Y, et al. Concomitant chronic kidney disease increases the recurrence of atrial fibrillation after catheter ablation of atrial fibrillation: A mid-term follow-up. Heart Rhythm, 2011, 8(3): 335-341.
32. Leong-Sit P, Roux JF, Zado E, et al. Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. Circ Arrhythm Electrophysiol, 2011, 4: 11-14.
33. den Uijl DW, Delgado V, Bertini M, et al. Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation. Heart, 2011, 97(22): 1847-1851.
34. Catena C, Colussi G, Marzano L, et al. Aldosterone and the heart: from basic research to clinical evidence. Horm Metab Res, 2012, 44(3): 181-187.
35. 雷濤, 劉小慧, 羅太陽, 等. 培哚普利聯合醛固酮受體拮抗劑對心房纖顫犬心房電重構的影響. 心肺血管病雜志, 2010, 29(3): 233-237.
36. Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in atrial fibrosis: Mechanisms and fibrillation. J Mol Cell Cardiol, 2010, 48(3): 461-467.
37. 盧艷雨, 余江坤, 魯艷嬌, 等. 螺內酯對持續性房顫患者射頻消融術后的臨床療效分析. 河南醫學研究, 2015, 24(4): 12-14.
38. 周勇, 李莉, 徐志厶, 等. 心內膜微波消融治療永久性心房顫動. 中華心血管病雜志, 2008, 36(5): 402-403.
39. 伍繼初, 羅參香, 歐陽澤偉. 胺碘酮及氯沙坦對慢性房顫射頻消融術后心房結構及房顫復發的影響. 中國臨床藥理學與治療學, 2015, 2(3): 318-322.
40. 梁珍玲, 孫葉海, 彭衛平. 厄貝沙坦聯合胺碘酮治療陣發性心房顫動的療效. 中國老年學雜志, 2012, 32(13): 2836-2837.
41. Beukema WP, Sie HT, Misier AR, et al. Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified Maze procedure. Eur J Cardiothorac Surg, 2008, 34(4): 771-775.
42. Fasol R, Mdinhart J, Binder T. A modified and simplified radiofrequency ablation in patients with mitral valve disease. J Thorac Cardiovasc Surg, 2005, 129(1): 215-217.
43. Parvez B, Shoemaker MB, Muhammad R, et al. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. Heart Rhythm, 2013, 10(6): 849-855..
44. Benjamin Shoemaker M, Muhammad R, Parvez B, et al. Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. Heart Rhythm, 2013, 10(3): 394-400.

Previous Article
Research progress of splanchnicectomy for cancer pain
Next Article
Removal of anterior mediastinal bronchogenic cysts by uniportal thoracoscopy in 26 patients

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Research progress on risk factors of recurrent atrial fibrillation after radiofrequency catheter ablation

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content